|
Post by yash on Aug 4, 2021 5:20:46 GMT -5
|
|
|
Post by peppy on Aug 8, 2021 19:37:47 GMT -5
I will see the humor, If Goldman Sacs sends an analyst to the Second Quarter Financial Results Conference Call and if Goldman will be involved in the question and answer. That will be the signal, things have changed?
5:00 PM (Eastern Time) on Wednesday, August 11, 2021.
(I said this last quarter as well, No GS)
|
|
|
Post by longliner on Aug 8, 2021 23:17:38 GMT -5
I will see the humor, If Goldman Sacs sends an analyst to the Second Quarter Financial Results Conference Call and if Goldman will be involved in the question and answer. That will be the signal, things have changed? 5:00 PM (Eastern Time) on Wednesday, August 11, 2021. (I said this last quarter as well, No GS) If so, keep an eye on the old hippie.
|
|
|
Post by derekewhitlock on Aug 11, 2021 9:35:10 GMT -5
Is my recall correct or is this the first CC in which the SP dropped going into call? I recall many CC’s in which the SP rose going into call and dropped subsequent but not reverse.
|
|
|
Post by sugarland on Aug 11, 2021 9:41:23 GMT -5
Is my recall correct or is this the first CC in which the SP dropped going into call? I recall many CC’s in which the SP rose going into call and dropped subsequent but not reverse. Agree. Was thinking the same.
|
|
|
Post by mcbone on Aug 11, 2021 9:42:19 GMT -5
Share price has been strangely dropping for some time now. But you would think that this is the first time in a long time that MNKD could actually have a good earnings report due to all of the prep work at the Danbury plant to produce Tyvaso. This is money flowing into MNKD from UTHR and it's the most important drug for both companies.
|
|
|
Post by factspls88 on Aug 11, 2021 9:55:12 GMT -5
Share price has been strangely dropping for some time now. But you would think that this is the first time in a long time that MNKD could actually have a good earnings report due to all of the prep work at the Danbury plant to produce Tyvaso. This is money flowing into MNKD from UTHR and it's the most important drug for both companies. Almost nothing surprises me with this stock. Biggest surprise would be a post-earnings gain that never looked back.
|
|
|
Post by novafett on Aug 11, 2021 14:58:02 GMT -5
Will there be a shout box? Shout! Shout!
|
|
|
Post by awesomo on Aug 11, 2021 15:01:47 GMT -5
Is my recall correct or is this the first CC in which the SP dropped going into call? I recall many CC’s in which the SP rose going into call and dropped subsequent but not reverse. Well, there was strong buying into the close soooo....
|
|
|
Post by peppy on Aug 11, 2021 15:02:31 GMT -5
|
|
|
Post by awesomo on Aug 11, 2021 15:04:47 GMT -5
- 2Q 2021 Total Revenues of $23.3 million; +54% vs. 2Q 2020
- 2Q 2021 Afrezza Net Revenue of $10.0 million; +43% vs. 2Q 2020
- $201.4 million of Cash, Cash Equivalents and Investments at June 30, 2021
|
|
|
Post by awesomo on Aug 11, 2021 15:17:20 GMT -5
Comparing revenue 1Q to 2Q 2021 Net revenue — commercial product sales 1Q: 8,099 2Q: 9,976
Revenue — collaborations and services 1Q: 9,337 2Q: 13,304
|
|
|
Post by Clement on Aug 11, 2021 15:22:38 GMT -5
"Total revenues were $23.3 million for the second quarter of 2021, an increase of $8.2 million, or 54%, reflecting Afrezza net revenue of $10.0 million and collaboration and services revenue of $13.3 million. Afrezza net revenue increased $3.0 million, or 43%, compared to $7.0 million in the second quarter of 2020 as a result of higher prescription demand, the negative effects of the COVID-19 pandemic in the prior year period, a more favorable mix of Afrezza cartridges, and price (including a lower gross-to-net deduction percentage of gross sales). Collaboration and services revenue for the second quarter of 2021 increased $5.2 million, or 64%, compared to the second quarter of 2020, primarily due to the Company’s collaboration with United Therapeutics." Afrezza net revenue of $10.0 million -- It will be interesting to hear this afternoon how that happened.
|
|
|
Post by Clement on Aug 11, 2021 15:30:48 GMT -5
I'm glad I bought more yesterday at 3.89.
|
|
|
Post by alethea on Aug 11, 2021 15:33:44 GMT -5
Continued progress on the financials. Afrezza net revenue continues to grow albeit not as quickly as most would like. Pretty good quarterly financials, especially considering the Pandemic.
|
|